Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

Author:

Nogova Lucia1ORCID,Mattonet Christian12,Scheffler Matthias1ORCID,Taubert Max3,Gardizi Masyar1,Sos Martin L.1ORCID,Michels Sebastian1,Fischer Rieke N.1,Limburg Meike1,Abdulla Diana S.Y.1,Persigehl Thorsten4,Kobe Carsten5,Merkelbach‐Bruse Sabine6,Franklin Jeremy7,Backes Heiko8,Schnell Roland9,Behringer Dirk10,Kaminsky Britta11,Eichstaedt Martina12,Stelzer Christoph13,Kinzig Martina13,Sörgel Fritz13,Tian Yingying314,Junge Lisa3,Suleiman Ahmed A.3,Frechen Sebastian3,Rokitta Dennis3,Ouyang Dongsheng1415,Fuhr Uwe3,Buettner Reinhard6,Wolf Jürgen1

Affiliation:

1. Department I of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Lung Cancer GroupUniversity of Cologne Cologne Germany

2. Onkologische Praxis Moers Moers Germany

3. Faculty of Medicine and University Hospital Cologne Center for Pharmacology Department I of Pharmacology University of Cologne Cologne Germany

4. Faculty of Medicine and University Hospital Cologne Institute for Diagnostics und Intervention Radiology University of Cologne Cologne Germany

5. Faculty of Medicine and University Hospital Cologne Department for Nuclear Medicine University of Cologne Cologne Germany

6. Faculty of Medicine and University Hospital Cologne Institute for PathologyUniversity of Cologne Cologne Germany

7. Faculty of Medicine Institute for Medical Statistics and Bioinformatics University of Cologne Cologne Germany

8. Max Planck Institute for Metabolism Research Cologne Germany

9. Praxis for Medical Oncology and Haematology (PIOH) Frechen Germany

10. Heamatology and Oncology Augusta Hospital Bochum Germany

11. Bethanien Hospital Solingen Germany

12. Medical Oncology and Haematology St. Marien Hospital Düren Germany

13. Institute for Biomedical and Pharmaceutical Research (IBMP) Nürnberg Germany

14. Department of Clinical Pharmacology Xiangya HospitalCentral South University Changsha China

15. Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples Changsha China

Funder

Bayer

Novartis

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3